SCHEMBL15044071

SCHEMBL15044071

CCC(CO)(CO)C(O)CO

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16074677 0.94 TSHR (0.33) TSHRTDP1DPP4
SCHEMBL9521759 0.83 TSHR (0.46) TSHRDPP4
SCHEMBL3610234 0.82 DPP4 (0.38) TDP1DPP4
SCHEMBL28192136 0.79 TSHR (0.31) TSHRTDP1
SCHEMBL28477505 0.79 TSHR (0.35) TSHRTDP1DPP4
SCHEMBL5675923 0.78 TSHR (0.46) TSHRDPP4
SCHEMBL17464903 0.77 CYP2C19 (0.34) TSHR
SCHEMBL7047457 0.77 DPP4 (0.35) TSHRTDP1DPP4
SCHEMBL8103459 0.75 THRB (0.40) TDP1DPP4
SCHEMBL2194664 0.75 DPP4 (0.32) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298058-A1 HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE SHIONOGI & CO (JP) 2017-10-19 US disclosed
US-9550763-B2 Heterocyclic ring and carbocyclic derivative SHIONOGI & CO., LTD. (JP) 2017-01-24 US disclosed
US-20160024072-A1 Heterocyclic Ring and Carbocyclic Derivative SHIONOGI & CO., LTD. (JP) 2016-01-28 US disclosed
WO-2013118855-A1 HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE 塩野義製薬株式会社 (JP) 2013-08-15 WO disclosed
WO-2013089212-A1 SUBSTITUTED TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 塩野義製薬株式会社 (JP) 2013-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298058-A1 HETEROCYCLIC RING AND CARBOCYCLIC DERIVATIVE P2RX3, P2RX7, P2RX2 TSHR 737/4885TDP1 4738/4885DPP4 3803/4885
US-20160024072-A1 Heterocyclic Ring and Carbocyclic Derivative P2RX3, P2RX7, P2RX2 TSHR 737/4885TDP1 4738/4885DPP4 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.